MRNA-1283 clinical trials
Also written mRNA-1283.
How each study uses MRNA-1283 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the MRNA-1283 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- mRNA-1283
- 5
Studies by the year they started
5 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2021 | 2 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test MRNA-1283.
- Dec 2026A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing FormulationsPhase 4 · ModernaTX, Inc.
- Jun 2027A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)Phase 4 · ModernaTX, Inc.
Studies
Open first, then newest update. How each study uses MRNA-1283 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of AgeRecruitingPhase 2ModernaTX, Inc.NCT07808697Written as mRNA-1283
- A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing FormulationsRecruitingPhase 4ModernaTX, Inc.NCT07863635Written as mRNA-1283
- A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)Active, not recruitingPhase 4ModernaTX, Inc.NCT07266558Written as mRNA-1283
- A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine BoostersCompletedPhase 2ModernaTX, Inc.NCT05137236Written as mRNA-1283
- A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19CompletedPhase 1ModernaTX, Inc.NCT04813796Written as mRNA-1283
What changed recently
From the registry's own updates since Oct 18, 2026.